russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2024-5841QCNIVCrussjcardiol-5841Research ArticleВ ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУSUPPORTING A PRACTITIONERОбновленные рекомендации Европейского общества кардиологов по сердечной недостаточности 2023 года2023 Updated European Society of Cardiology guidelines on heart failurehttps://orcid.org/0000-0001-9842-962XРакишеваА. Г.RakishevaA. G.

Ракишева Амина Галимжановна — доктор PhD, зам. директора по клинической работе

Алматы

Almaty

amina.grakisheva@gmail.comКуанышбековаР. Т.KuanyshbekovaR. T.

Куанышбекова Роза Тохтаналиевна — д. м. н., профессор, директор

Алматы

Almaty

kardiocenter_almaty@mail.ruКГП на ПХВ Городской кардиологический центр Управления общественного здравоохранения города АлматыКазахстанCity Cardiology CenterKazakhstan202405042024292SОбразование58415841Copyright © Ракишева А.Г., Куанышбекова Р.Т., 20242024Ракишева А.Г., Куанышбекова Р.Т.Rakisheva A.G., Kuanyshbekova R.T.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/5841

В статье представлены новые положения рекомендаций Европейского общества кардиологов по ведению пациентов с острой и хронической сердечной недостаточности 2023 года с обсуждением ключевых аспектов, включая их основные принципы, рекомендации по лекарственному и нефармакологическому лечению, а также их потенциальное влияние на ведение пациентов с сердечной недостаточностью.

This article presents the new data of the 2023 European Society of Cardiology guidelines for the management of patients with acute and chronic heart failure, discussing key aspects, including their basic principles, recommendations for pharmacological and non-pharmacological treatment. In addition, their potential impact on the management of patients with heart failure was described.

хроническая сердечная недостаточностьдиуретикиэмпаглифлозиндапаглифлозинchronic heart failurediureticsempagliflozindapagliflozinReferencesConrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: A population-based study of 4 million individuals. Lancet. 2018;391:572-80. doi:10.1016/S0140-6736(17)32520-5.Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: A population-based study of 4 million individuals. Lancet. 2018;391:572-80. doi:10.1016/S0140-6736(17)32520-5.McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022:24(1):4-131. doi:10.1093/eurheartj/ehab368.McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022:24(1):4-131. doi:10.1093/eurheartj/ehab368.Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23:352-80. doi:10.1002/ejhf.2115.Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23:352-80. doi:10.1002/ejhf.2115.McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-39. doi:10.1093/eurheartj/ehad195.McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-39. doi:10.1093/eurheartj/ehad195.Docherty KF, Lam CSP, Rakisheva A, et al. Heart failure diagnosis in the general community — Who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2023; 25(8):1185-98. doi:10.1002/ejhf.2946.Docherty KF, Lam CSP, Rakisheva A, et al. Heart failure diagnosis in the general community — Who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2023; 25(8):1185-98. doi:10.1002/ejhf.2946.Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-61. doi:10.1056/NEJMoa2107038.Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-61. doi:10.1056/NEJMoa2107038.Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089-98. doi:10.1056/NEJMoa2206286.Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089-98. doi:10.1056/NEJMoa2206286.Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757-67. doi:10.1016/S0140-6736(22)01429-5.Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757-67. doi:10.1016/S0140-6736(22)01429-5.Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387:1185-95. doi:10.1056/NEJMoa2203094.Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387:1185-95. doi:10.1056/NEJMoa2203094.Trullàs JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. 2023;44:411-21. doi:10.1093/eurheartj/ehac689.Trullàs JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. 2023;44:411-21. doi:10.1093/eurheartj/ehac689.Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022; 28:568-74. doi:10.1038/s41591-021-01659-1.Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022; 28:568-74. doi:10.1038/s41591-021-01659-1.Lee DS, Straus SE, Farkouh ME, et al. Trial of an intervention to improve acute heart failure outcomes. N Engl J Med. 2023;388:22-32. doi:10.1056/NEJMoa2211680.Lee DS, Straus SE, Farkouh ME, et al. Trial of an intervention to improve acute heart failure outcomes. N Engl J Med. 2023;388:22-32. doi:10.1056/NEJMoa2211680.Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400:1938-52. doi:10.1016/S0140-6736(22)02076-1.Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400:1938-52. doi:10.1016/S0140-6736(22)02076-1.Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-46. doi:10.1056/NEJMoa2024816.Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-46. doi:10.1056/NEJMoa2024816.The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117-27. doi:10.1056/NEJMoa2204233.The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117-27. doi:10.1056/NEJMoa2204233.Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-306. doi:10.1056/NEJMoa1811744.Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-306. doi:10.1056/NEJMoa1811744.Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384:129-39. doi:10.1056/NEJMoa2030186.Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384:129-39. doi:10.1056/NEJMoa2030186.Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor MetaAnalysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788-801. doi:10.1016/S0140-6736(22)02074-8.Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor MetaAnalysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788-801. doi:10.1016/S0140-6736(22)02074-8.Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219-29. doi:10.1056/NEJMoa2025845.Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219-29. doi:10.1056/NEJMoa2025845.Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252-63. doi:10.1056/NEJMoa2110956.Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252-63. doi:10.1056/NEJMoa2110956.Filippatos G, Pitt B, Agarwal R, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail. 2022;24:996-1005. doi:10.1002/ejhf.2469.Filippatos G, Pitt B, Agarwal R, et al. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail. 2022;24:996-1005. doi:10.1002/ejhf.2469.Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400:2199-209. doi:10.1016/S0140-6736(22)02083-9.Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400:2199-209. doi:10.1016/S0140-6736(22)02083-9.Salah HM, Savarese G, Rosano GMC, et al. Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis. ESC Heart Fail. 2023;10:1473- 80. doi:10.1002/ehf2.14310.Salah HM, Savarese G, Rosano GMC, et al. Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis. ESC Heart Fail. 2023;10:1473- 80. doi:10.1002/ehf2.14310.Graham FJ, Pellicori P, Kalra PR, et al. Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis. Eur J Heart Fail. 2023;25:528-37. doi:10.1002/ejhf.2810.Graham FJ, Pellicori P, Kalra PR, et al. Intravenous iron in patients with heart failure and iron deficiency: an updated meta-analysis. Eur J Heart Fail. 2023;25:528-37. doi:10.1002/ejhf.2810.Vukadinovic D, Abdin A, Emrich I, et al. Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis. Clin Res Cardiol. 2023;112:954-66. doi:10.1007/s00392-023-02207-2.Vukadinovic D, Abdin A, Emrich I, et al. Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis. Clin Res Cardiol. 2023;112:954-66. doi:10.1007/s00392-023-02207-2.Anker SD, Khan MS, Butler J, et al. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: a Bayesian meta-analysis. Eur J Heart Fail. 2023;25(7):1080-90. doi:10.1002/ejhf.2860.Anker SD, Khan MS, Butler J, et al. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: a Bayesian meta-analysis. Eur J Heart Fail. 2023;25(7):1080-90. doi:10.1002/ejhf.2860.

The authors declare that there are no conflicts of interest present.